Pay in 4 interest-free payments of $7.35 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
GIP (114) is a partial agonist of GIPR
When administered together, GHRH analogs and ghrelin mimetics produce synergistic GH pulses [1] [2]
The most significant clinical evidence for retatrutide to date comes from a Phase 2 trial published in the New England Journal of Medicine in 2023 (Jastreboff et al., NEJM 2023)
The chart below shows the Retatrutide weight loss results based on the dose and duration: The Retatrutide clinical trials are still underway with a planned Phase IV beyond the current Phase III
Lucioni, A
US$ 20.26
US$ 25.65
US$ 20.37
US$ 26.77
